Previous Close | 1.5510 |
Open | 1.5280 |
Bid | 1.5370 x 700000 |
Ask | 1.6030 x 1100000 |
Day's Range | 1.5280 - 1.5280 |
52 Week Range | 1.3390 - 2.4020 |
Volume | |
Avg. Volume | 98 |
Market Cap | 6.752B |
Beta (5Y Monthly) | 0.62 |
PE Ratio (TTM) | 15.28 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.04 (2.28%) |
Ex-Dividend Date | Jul 26, 2024 |
1y Target Est | N/A |
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly endanger health and cost lives, but it also perpetuates a vicious cycle of inequity. People living in the most vulnerable situations including pregnant women and children under 5 years of age continue to be disproportionately impacted.
The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximately US$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Pharma for a triple artemisinin combination drug (Artemether-Lumefantrine-Amodiaquine fixed-dose formulation) against malaria in Africa and Southeast Asia, to accelerate the development and commercialization of this new drug.
Acceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun PharmaWALTHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that a New Drug Application (NDA) for tenapanor has been accepted for review by China’s Center for Drug Evaluation of the National Medical